The CD30+ DLBCL subtype is a diverse entity, with subsets differing in the scope of mutations, transcriptome, TME landscapes, and clinical outcomes, presenting a rationale for future mechanism-based targeted therapy of DLBCL [422]. The gene discussed is TNFRSF8; the disease is diffuse large B-cell lymphoma.